Denosumab biosimilar - GlycoNex
Alternative Names: SPD Denosumab biosimilar - GlycoNex; SPD-8Latest Information Update: 14 Jan 2025
At a glance
- Originator GlycoNex; Mitsubishi Gas Chemical - Nisshin Pharma (JV)
- Developer GlycoNex
- Class Antihypercalcaemics; Antineoplastics; Antirheumatics; Calcium regulators; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Osteoporosis
- Preclinical Cancer